Consun Pharmaceutical Group (FRA:C1P) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C1P Consun Pharmaceutical Group Ltd FRA:C1P
78 GF Score
Price €1.50
GF Value €0.92
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Consun Pharmaceutical Group Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Consun Pharmaceutical Group Valuation Rank Related Terms

FRA:C1P
78GF Score
Consun Pharmaceutical Group Ltd FRA:C1P
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Consun Pharmaceutical Group (FRA:C1P) Overvalued in 2026?

Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued. The current stock price of €1.50 is trading 63% above its estimated GF Value™ of €0.92. GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.

Key valuation signals for FRA:C1P:

  • Valuation Rank:
  • GF Value™: €0.92 vs. price of €1.50 (63% above fair value)
  • GF Score™: 78/100 with 1 warning sign

No single metric tells the full story. See the FRA:C1P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Consun Pharmaceutical Group Business Description

Other Exchanges 01681:Hong Kong
Address 71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
78GF Score

Get the complete analysis for FRA:C1P

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.50
Price
€0.92
GF Value